<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02656329</url>
  </required_header>
  <id_info>
    <org_study_id>GE-122-020</org_study_id>
    <secondary_id>2015-001464-19</secondary_id>
    <nct_id>NCT02656329</nct_id>
  </id_info>
  <brief_title>International Study to Determine if AdreView Heart Function Scan Can be Used to Identify Patients With Mild or Moderate Heart Failure (HF) That Benefit From Implanted Medical Device</brief_title>
  <acronym>ADMIRE-ICD</acronym>
  <official_title>AdreView™ Myocardial Imaging for Risk Evaluation - A Multicentre Trial to Guide ICD Implantation in NYHA Class II &amp; III Heart Failure Patients With 25%≤LVEF≤35%</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GE Healthcare</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Advanced Clinical, LLC</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>TFS</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>H2O Clinical LLC</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>AG Mednet Inc.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>ICON CEAC</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>ICON Clinical</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>ABX CRO</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>TransPerfect</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>GE Healthcare</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an event-driven Phase IIIb, multicentre, randomised, clinical study to demonstrate
      the efficacy of AdreView™ imaging for appropriately guiding the decision of implantable
      cardioverter defibrillator (ICD) implantation, in New York Health Association (NYHA) class II
      and III heart failure participants with 25%&lt;=left ventricular ejection fraction (LVEF)&lt;=35%,
      and in particular, for identifying participants who are at low risk for sudden cardiac death
      and who would not benefit, or may suffer harm, from implantation of an ICD device.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Sponsor discretion (low recruitment rate)
  </why_stopped>
  <start_date type="Actual">December 30, 2015</start_date>
  <completion_date type="Actual">May 4, 2018</completion_date>
  <primary_completion_date type="Actual">May 4, 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>All-cause Mortality</measure>
    <time_frame>From randomization until the end of the follow-up period (median 304 days)</time_frame>
    <description>All-cause mortality included all reported deaths of participants during the study due to any cause. Percentage of participants who died due to any cause were reported.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Events of Complications of Device: H/M &gt;=1.6 in Full Analysis Set</measure>
    <time_frame>From randomization until the end of the follow-up period (median 304 days)</time_frame>
    <description>Composite of the percentage of participants with events of hospitalization or death related to major complications of device implantation (i.e., need for thoracotomy, pericardiocentesis, or vascular surgery), complications of long-term device therapy (i.e., infection not leading to hospitalization, lead and/or generator removal/replacement, inappropriate shocks, explanation), and combined as 'complications of device' for participants with H/M &gt;=1.6. Participants who were alive at time of database lock (DBL) were censored at the last known-alive date.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Cardiac Death</measure>
    <time_frame>From randomization until the end of the follow-up period (median 304 days)</time_frame>
    <description>Cardiac death composed of sudden cardiac death, death due to cardiac arrhythmia, death due to heart failure, and death due to other cardiovascular causes.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Hospitalization for Cardiovascular Cause</measure>
    <time_frame>From randomization until the end of the follow-up period (median 304 days)</time_frame>
    <description>Percentage of participants who were hospitalized for cardiovascular cause were reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With All-Cause Hospitalization</measure>
    <time_frame>From randomization until the end of the follow-up period (median 304 days)</time_frame>
    <description>Percentage of participants with all-cause hospitalization were reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Events (Composite of the Occurrence of Resuscitated Life-Threatening Ventricular Tachycardia, Unstable Ventricular Tachyarrhythmias, Sudden Cardiac Death [SCD] and Resuscitated Cardiac Arrest)</measure>
    <time_frame>From randomization until the end of the follow-up period (median 304 days)</time_frame>
    <description>Percentage of participants with composite events i.e occurrence of resuscitated life-threatening ventricular tachycardia, unstable ventricular tachy-arrhythmias, SCD and resuscitated cardiac arrest were reported. Participants who were alive at time of database lock (DBL) were censored at the last known-alive date.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Syncope</measure>
    <time_frame>From randomization until the end of the follow-up period (median 304 days)</time_frame>
    <description>Percentage of participants with Syncope were reported. Participants who were alive at time of DBL were censored at the last known-alive date by date of DBL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Implantable Cardioverter Defibrillator (ICD) Implantation</measure>
    <time_frame>From randomization until the end of the follow-up period (median 304 days)</time_frame>
    <description>Percentage of participants with ICD implantation were reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Events of Complications of Device</measure>
    <time_frame>From randomization until the end of the follow-up period (median 304 days)</time_frame>
    <description>Composite of the percentage of participants with events of hospitalization or death related to major complications of device implantation (i.e., need for thoracotomy, pericardiocentesis, or vascular surgery), complications of long-term device therapy (i.e., infection not leading to hospitalization, lead and/or generator removal/replacement, inappropriate shocks, explanation), and combined as 'complications of device'.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">395</enrollment>
  <condition>Heart Failure</condition>
  <arm_group>
    <arm_group_label>AdreView™</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received 1 intravenous injection of 10 mCi (370 MBq) of AdreView™ (Iobenguane I-123 Injection). Participants with AdreView™ Heart-to-Mediastinal ratio (H/M) &lt;1.6 underwent Implantable Cardioverter Defibrillator (ICD) device implantation and H/M &gt;= 1.6 continued to receive Guideline-Directed Optimal Medical Therapy (GDMT) according to clinical standard practice.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard of Care</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received 1 intravenous injection of 10 mCi (370 MBq) of AdreView™ (Iobenguane I-123 Injection) and underwent ICD implantation and were followed up in accordance with internationally accepted Heart Failure (HF) guidelines.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Iobenguane I -123 Injection</intervention_name>
    <description>Iobenguane I-123 Injection, AdreView. All participants scheduled for an Iobenguane I-123 Injection, AdreView scan.</description>
    <arm_group_label>AdreView™</arm_group_label>
    <other_name>AdreView</other_name>
    <other_name>Iobenguane I-123 Injection</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Implantable Cardioverter Defibrillator</intervention_name>
    <description>In the Iobenguane I-123 Injection group, participants with H/M ratio less or equal to 1.6 underwent ICD device implantation, while those with H/M ratio greater than or equal to 1.6 did not undergo ICD implantation.</description>
    <arm_group_label>AdreView™</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Thyroid blocking</intervention_name>
    <description>Participants received a thyroid blocking agent before the Iobenguane I-123 Injection, AdreView, scan unless medically not indicated, according to local practice.</description>
    <arm_group_label>AdreView™</arm_group_label>
    <other_name>Potassium Iodide</other_name>
    <other_name>Potassium Perchlorate</other_name>
    <other_name>Lugol's Solution</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Iobenguane I -123 Injection</intervention_name>
    <description>Iobenguane I-123 Injection, AdreView. All participants scheduled for an Iobenguane I-123 Injection, AdreView scan.</description>
    <arm_group_label>Standard of Care</arm_group_label>
    <other_name>AdreView</other_name>
    <other_name>Iobenguane I-123 Injection</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Implantable Cardioverter Defibrillator</intervention_name>
    <description>All participants allocated to the SoC (control) group underwent ICD implantation.</description>
    <arm_group_label>Standard of Care</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Participants &gt;=18 years of age at the time dated informed consent was obtained.

          -  Female participants must be pre-menarchal, surgically sterile (had a documented
             bilateral oophorectomy and/or documented hysterectomy), postmenopausal (cessation of
             menses for more than 1 year), non-lactating, or, if of childbearing potential, a serum
             or urine pregnancy test with the results known prior to AdreView (Iobenguane I-123
             Injection) administration) was negative.

          -  Participants willing and able to comply with all study procedures and a signed and
             dated informed consent was obtained before any study-procedure was carried out.

          -  Heart failure NYHA class II or III for symptoms, participants with ischemic or
             non-ischemic heart disease, eligible for ICD implantation as per each site's standard
             of practice.

          -  Non-ischemic dilated cardiomyopathy or ischemic heart disease of at least 3 months
             duration receiving guideline-directed optimal medical therapy.

          -  25%≤LVEF≤35%, performed within 3 months before or at time of enrollment, as measured
             by radionuclide ventriculography, or electrocardiogram [ECG]-gated SPECT myocardial
             perfusion imaging [MPI], or magnetic resonance imaging [MR], computed tomography [CT],
             or 3D or 2D echocardiography [Simpson's or multidisc method only, M-mode
             echocardiography was not accepted].

        In case LVEF measurement was performed within 3 months before enrollment, measurement
        should be performed at least 40 days after a hospitalization for HF or acute coronary
        syndrome (including myocardial infarction), and to be valid, method of measurement should
        be in accordance with the protocol and the imaging exam should be made available to the
        Sponsor in digital format. In case several valid LVEF measurements are available, the
        closest to enrollment will be used for inclusion determination.

          -  Clinically stable heart failure in the medical judgment of the investigator (i.e. no
             significant changes in medication, no worsening of symptoms, no unscheduled visits to
             the doctor's office) for the past 30 days and no hospitalization for heart failure or
             acute coronary syndrome (including myocardial infarction) in the past 40 days.

          -  Reasonable expectation of meaningful survival for at least 1 year.

        Exclusion Criteria:

          -  Participants with existing ICD or participant having an indication of ICD implantation
             for secondary prevention of sudden cardiac death.

          -  Hospitalization for HF or for acute coronary syndrome in the previous 40 days.

          -  Participants where a cardiac resynchronisation therapy (CRT) was planned or indicated.

          -  Other indication for placement of device (sustained ventricular tachycardia,
             resuscitated sudden death, need for atrioventricular pacing).

          -  NYHA class I or class IV symptoms at the time of study entry.

          -  Participants with chronic renal insufficiency defined as serum creatinine ≥ 3 mg/dl
             (or ≥ 265.2 µmol/L).

          -  American College of College-American Heart Association (ACC-AHA) class III or class IV
             (unstable) angina.

          -  Known or suspected hypersensitivity/allergy to Iobenguane or to any of the excipients
             an Adreview (Iobenguane I-131 injection).

          -  Participant who was pregnant or plans to become pregnant within 2 weeks after AdreView
             (Iobenguane I-123 Injection) administration.

          -  Participant who had used any medication in the 2 weeks before AdreView (Iobenguane
             I-123 Injection) that could interfere with the test: e.g. but not limited to
             amitriptyline or derivatives, imipramine or derivatives, other antidepressants or
             drugs known or suspected to inhibit the norepinephrine transporter, antihypertensives
             that deplete norepinephrine stores or inhibit reuptake, sympathomimetic amines or
             cocaine.

          -  Participants that had a medical condition that could interfere with the AdreView test
             (e.g. but not limited to left ventricular assist device (LVAD), or prior heart
             transplant).

          -  Participants who participated in a clinical study involving a drug or device within 30
             days prior to study entry and participants participating in any other clinical study.

          -  Participants having serious non-cardiac medical condition associated with significant
             elevation of plasma catecholamines, including pheochromocytoma.

          -  Participants with a clinical diagnosis of (or being treated for) Parkinson's disease
             or Multiple System Atrophy.

          -  The participant had participated in a research study using ionizing radiation in the
             previous 12 months.

          -  Participants previously randomized in this study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Vascular Biology and Hypertension Program, University of Alabama at Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Comprehensive Cardiovascular Medical Group</name>
      <address>
        <city>Bakersfield</city>
        <state>California</state>
        <zip>93309</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sharp Grossmont Hospital</name>
      <address>
        <city>La Mesa</city>
        <state>California</state>
        <zip>91942</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yale New Haven Hospital</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06510</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>VA Connecticut Healthcare System (VACHS)</name>
      <address>
        <city>West Haven</city>
        <state>Connecticut</state>
        <zip>06516</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cardiology Physicians PA/Red Clay Research, LLC</name>
      <address>
        <city>Newark</city>
        <state>Delaware</state>
        <zip>19713</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bethesda Health</name>
      <address>
        <city>Boynton Beach</city>
        <state>Florida</state>
        <zip>33435</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Florida Health Jacksonville</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Miami Hospital</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cardiology Consultants</name>
      <address>
        <city>Pensacola</city>
        <state>Florida</state>
        <zip>32501</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>South Miami Heart Specialists</name>
      <address>
        <city>South Miami</city>
        <state>Florida</state>
        <zip>33143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tampa General Hospital</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33606</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of South Florida</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33609</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Augusta University</name>
      <address>
        <city>Augusta</city>
        <state>Georgia</state>
        <zip>30912</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rush University Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwestern University</name>
      <address>
        <city>Evanston</city>
        <state>Illinois</state>
        <zip>60208</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MMP ME Health Cardiology</name>
      <address>
        <city>Scarborough</city>
        <state>Maine</state>
        <zip>04074</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MedStar Shah Medical Group</name>
      <address>
        <city>Charlotte Hall</city>
        <state>Maryland</state>
        <zip>20622</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boston Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02118</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Cardiology, K-14 (Henry Ford Health System)</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regions Hospital and Regions Heart Center Clinic</name>
      <address>
        <city>Saint Paul</city>
        <state>Minnesota</state>
        <zip>55101</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Montefiore Medical Center</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10467</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University at Buffalo</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Advanced Cardiology Group</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>WakeMed</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27610</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Veterans Affairs North Texas Healthcare System</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75216</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Houston Methodist Hospital</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Institute of Cardiology, PA</name>
      <address>
        <city>McKinney</city>
        <state>Texas</state>
        <zip>75071</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Victoria Heart and Vascular Center</name>
      <address>
        <city>Victoria</city>
        <state>Texas</state>
        <zip>77901</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Calgary</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T2N 1N4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Alexandra Hospital</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T5H3V9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>London Health Sciences Centre</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 5A5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Michael's Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5B 1W8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Montreal Heart Institute</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H1T 1C8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CIUSSS de L'Estrie - CHUS Hopital Fleurimont</name>
      <address>
        <city>Sherbrooke</city>
        <state>Quebec</state>
        <zip>J1H 5N4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Universitaire De Cardiologie Et De Pneumologie De Quebec</name>
      <address>
        <city>Quebec</city>
        <zip>G1V 4G5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fakultni nemocnice Brno Bohunice</name>
      <address>
        <city>Brno</city>
        <zip>625 00</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fakultni nemocnice u sv. Anny v Brne</name>
      <address>
        <city>Brno</city>
        <zip>656 91</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>FN Hradec Kralove</name>
      <address>
        <city>Hradec Kralove</city>
        <zip>500 05</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Krajska nemocnice Liberec</name>
      <address>
        <city>Liberec</city>
        <zip>460 63</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fakultni nemocnice Plzen</name>
      <address>
        <city>Lochotín</city>
        <zip>304 60</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fakultni nemocnice v Kralovske Vinohrady</name>
      <address>
        <city>Praha 10</city>
        <zip>100 34</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fakultni nemocnice v Motole</name>
      <address>
        <city>Praha 5</city>
        <zip>150 06</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Masarykova nemocnice v Usti nad Labem</name>
      <address>
        <city>Usti nad Labem</city>
        <zip>40001</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHR Metz-Thionville - Site de Mercy</name>
      <address>
        <city>Ars Laquenexy</city>
        <zip>57530</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CH Antoine Beclere</name>
      <address>
        <city>Clamart</city>
        <zip>92140</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Clermont-Ferrand, 63003 Montalembert</name>
      <address>
        <city>Clermont-Ferrand</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Henri Mondor</name>
      <address>
        <city>Créteil</city>
        <zip>94010</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHRU de Lille</name>
      <address>
        <city>Lille</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital de Rangueil CHU Toulouse</name>
      <address>
        <city>Toulouse Cedex 9</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique Pasteur</name>
      <address>
        <city>Toulouse</city>
        <zip>31300</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopitaux de Brabois Chu Nancy</name>
      <address>
        <city>Vandoeuvre Les Nancy Cedex</city>
        <zip>54511</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kliniken Maria Hilf GmbH, Klinik fur Nuklearmedizin</name>
      <address>
        <city>Monchengladbach</city>
        <zip>41063</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinik &amp; Poliklinik fur Nuklearmedizin, LMU, Campus Grobhader</name>
      <address>
        <city>Munich</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Varosmajori Sziv es Ergyogyaszati Klinika</name>
      <address>
        <city>Budapest</city>
        <zip>1112</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Budai Irgalmasrendi Korhaz</name>
      <address>
        <city>Budapest</city>
        <zip>H-1023</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gottsegen Gyorgy Orszagos Kardiologiai Intezet</name>
      <address>
        <city>Budapest</city>
        <zip>H-1134</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Magyar Honvedseg Egeszsegugyi Kozpont Kardiológia Osztály/Nuklearis Medicina Osztaly</name>
      <address>
        <city>Budapest</city>
        <zip>H-1134</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Semmelweis Egyetem Nuklearis Medicina Kozpont</name>
      <address>
        <city>Budapest</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Debreceni Egyetem, Kardiologia Intezet and ScanoMed Nuclear Medicine Institute</name>
      <address>
        <city>Debrecen</city>
        <zip>4032</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Coromed-SMO ft.</name>
      <address>
        <city>Pécs</city>
        <zip>H-7623</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Universitaria G. Martino</name>
      <address>
        <city>Messina</city>
        <zip>98125</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Area Cardiologia Critica - IRCCS Centro Cardiologico Mozino</name>
      <address>
        <city>Milano</city>
        <zip>20138</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Santa Croce</name>
      <address>
        <city>Moncalieri</city>
        <zip>10024</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliero-Universitaria Federico II Dipartimento ad Attivita Integrata di Cardiologia,Cardiochirurgia ed Emergenze Cardiovascolari</name>
      <address>
        <city>Napoli</city>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliero-Universitaria Maggiore della Carità, Dipartimento Cardiologico, Cardiologia 1</name>
      <address>
        <city>Novara</city>
        <zip>28100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituti Clinici Scientifici Maugeri Spa Societa Benefit</name>
      <address>
        <city>Pavia</city>
        <zip>27100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dipartimento di Scienze Cardiovascolari, Respiratorie Neufrologiche e Geriatriche - Universita di Roma &quot;La Sapienza&quot;</name>
      <address>
        <city>Rome</city>
        <zip>00161</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Santa Maria di Ca' Foncello</name>
      <address>
        <city>Treviso</city>
        <zip>31100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Venezia Mestre - Azienda ULSS 12 &quot;Veneziana&quot;</name>
      <address>
        <city>Venezia</city>
        <zip>30174</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale dell'Angelo, 30174, Venezia Mestre</name>
      <address>
        <city>Venice</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Onze Lieve Vrouwen Gasthuis</name>
      <address>
        <city>Amsterdam</city>
        <zip>1091 AC</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Academic Medical Center</name>
      <address>
        <city>Amsterdam</city>
        <zip>1105 AZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Amphia Zickenhuis</name>
      <address>
        <city>Breda</city>
        <zip>4818 CK</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Leiden University Medical Center</name>
      <address>
        <city>Leiden</city>
        <zip>2333 ZA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maastricht University Medical Center</name>
      <address>
        <city>Maastricht</city>
        <zip>6229 HX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Uniwersytecki Szpital Kliniczny w Bialymstoku</name>
      <address>
        <city>Bialystok</city>
        <zip>15-276</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Uniwersyteckie Centrum Kliniczne</name>
      <address>
        <city>Gdańsk</city>
        <zip>80-952</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Samodzielny Publiczny Szpital Kliniczny Nr 7 Slaskiego Uniwersytetu Medycznego w Katowicach</name>
      <address>
        <city>Katowice</city>
        <zip>40-635</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Krakowski Szpital Specjalistyczny im. Jana Pawla II</name>
      <address>
        <city>Krakow</city>
        <zip>31-202</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wojskowy Instytut Medyczny</name>
      <address>
        <city>Warsaw</city>
        <zip>04-141</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Samodzielny Publiczny Centralny Szpital Kliniczny</name>
      <address>
        <city>Warsaw</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dolnośląski Szpital Specjalistyczny im. T. Marciniaka Centrum Medycyny Ratunkowej</name>
      <address>
        <city>Wrocław</city>
        <zip>54-049</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinico Universitario Virgen de la Arrixaca</name>
      <address>
        <city>El Palmar (Murcia)</city>
        <zip>30120</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen de las Nieves</name>
      <address>
        <city>Granada</city>
        <zip>18014</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Leon</name>
      <address>
        <city>León</city>
        <zip>24071</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Ramon y Cajal</name>
      <address>
        <city>Madrid</city>
        <zip>28034</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinico Universitario San Carlos</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen de la Victoria</name>
      <address>
        <city>Malaga</city>
        <zip>29010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Son Espases</name>
      <address>
        <city>Palma de Mallorca (Illes Balears)</city>
        <zip>07120</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clínico de Salamanca</name>
      <address>
        <city>Salamanca</city>
        <zip>37002</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario San Juan de Alicante</name>
      <address>
        <city>San Juan Alicante</city>
        <zip>03550</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario Universitario de Santiago</name>
      <address>
        <city>Santiago De Compostela (A Coruña)</city>
        <zip>15706</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital General Universitario de Valencia</name>
      <address>
        <city>Valencia</city>
        <zip>46014</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Czechia</country>
    <country>France</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Poland</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Czech Republic</country>
  </removed_countries>
  <verification_date>April 2019</verification_date>
  <study_first_submitted>January 7, 2016</study_first_submitted>
  <study_first_submitted_qc>January 12, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 14, 2016</study_first_posted>
  <results_first_submitted>April 26, 2019</results_first_submitted>
  <results_first_submitted_qc>April 26, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">May 22, 2019</results_first_posted>
  <last_update_submitted>April 26, 2019</last_update_submitted>
  <last_update_submitted_qc>April 26, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">May 22, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Heart Failure (HF)</keyword>
  <keyword>Single photon emission computer tomography scan (SPECT)</keyword>
  <keyword>Implantable cardioverter defibrillator (ICD)</keyword>
  <keyword>Left Ventricular ejection fraction (LVEF)</keyword>
  <keyword>New York Health Association (NYHA)</keyword>
  <keyword>Metaiodobenzylguanidine (mIBG)</keyword>
  <keyword>123I-iobenguane</keyword>
  <keyword>Heart-to-mediastinal ratio (H/M)</keyword>
  <keyword>ADMIRE-ICD (AdreView Myocardial Imaging for Risk Evaluation - Implantable Cardioverter Defibrillator</keyword>
  <keyword>All-cause mortality</keyword>
  <keyword>Cardiac mortality</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>3-Iodobenzylguanidine</mesh_term>
    <mesh_term>Lugol's solution</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>May 11, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/29/NCT02656329/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>June 20, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/29/NCT02656329/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The Study was conducted at 70 centers in United States of America, Canada and Europe between 30 December 2015 and 04 May 2018. A total of 395 participants were enrolled in study, of which 52 were screen failures mainly due to exclusion criteria met.</recruitment_details>
      <pre_assignment_details>Out of 343 participants, 321 participants with 25% &lt;=left ventricular ejection fraction (LVEF) &lt;=35% were randomized in a 1:1 ratio to the AdreView™ group or Standard of Care (SoC) group stratified by enrolling center via an interactive web response system and 22 participants were not randomized but included in safety analysis set.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>AdreView™</title>
          <description>Participants received 1 intravenous injection of 10 millicurie (mCi) (370 MBq) of AdreView™ (Iobenguane I-123 Injection). Participants with AdreView™ Heart-to-Mediastinal ratio (H/M) &lt;1.6 underwent Implantable Cardioverter Defibrillator (ICD) device implantation and H/M &gt;= 1.6 continued to receive Guideline-Directed Optimal Medical Therapy (GDMT) according to clinical standard practice.</description>
        </group>
        <group group_id="P2">
          <title>Standard of Care</title>
          <description>Participants received 1 intravenous injection of 10 mCi (370 MBq) of AdreView™ (Iobenguane I-123 Injection) and underwent ICD implantation and were followed up in accordance with internationally accepted Heart Failure (HF) guidelines.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="164"/>
                <participants group_id="P2" count="157"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="164"/>
                <participants group_id="P2" count="157"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Study termination by Sponsor</title>
              <participants_list>
                <participants group_id="P1" count="150"/>
                <participants group_id="P2" count="142"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other than specified above</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Baseline population included randomized participants.</population>
      <group_list>
        <group group_id="B1">
          <title>AdreView™</title>
          <description>Participants received 1 intravenous injection of 10 mCi (370 MBq) of AdreView™ (Iobenguane I-123 Injection). Participants with AdreView™ Heart-to-Mediastinal ratio (H/M) &lt;1.6 underwent Implantable Cardioverter Defibrillator (ICD) device implantation and H/M &gt;= 1.6 continued to receive GDMT according to clinical standard practice.</description>
        </group>
        <group group_id="B2">
          <title>Standard of Care</title>
          <description>Participants received 1 intravenous injection of 10 mCi (370 MBq) of AdreView™ (Iobenguane I-123 Injection) and underwent ICD implantation and were followed up in accordance with internationally accepted HF guidelines.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="164"/>
            <count group_id="B2" value="157"/>
            <count group_id="B3" value="321"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="64.1" spread="9.40"/>
                    <measurement group_id="B2" value="62.1" spread="10.05"/>
                    <measurement group_id="B3" value="63.1" spread="9.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="35"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="57"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="129"/>
                    <measurement group_id="B2" value="135"/>
                    <measurement group_id="B3" value="264"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="26"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="142"/>
                    <measurement group_id="B2" value="140"/>
                    <measurement group_id="B3" value="282"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="19"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="149"/>
                    <measurement group_id="B2" value="137"/>
                    <measurement group_id="B3" value="286"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>All-cause Mortality</title>
        <description>All-cause mortality included all reported deaths of participants during the study due to any cause. Percentage of participants who died due to any cause were reported.</description>
        <time_frame>From randomization until the end of the follow-up period (median 304 days)</time_frame>
        <population>Analysis was performed on full analysis set (FAS) that was defined as participants included in the safety analysis set who were randomised to the AdreView™ group or the SoC group.</population>
        <group_list>
          <group group_id="O1">
            <title>AdreView™</title>
            <description>Participants received 1 intravenous injection of 10 mCi (370 MBq) of AdreView™ (Iobenguane I-123 Injection). Participants with AdreView™ H/M ratio &lt;1.6 underwent ICD device implantation and H/M ratio &gt;= 1.6 continued to receive GDMT according to clinical standard practice.</description>
          </group>
          <group group_id="O2">
            <title>Standard of Care</title>
            <description>Participants received 1 intravenous injection of 10 mCi (370 MBq) of AdreView™ (Iobenguane I-123 Injection) and underwent ICD implantation and were followed up in accordance with internationally accepted HF guidelines.</description>
          </group>
        </group_list>
        <measure>
          <title>All-cause Mortality</title>
          <description>All-cause mortality included all reported deaths of participants during the study due to any cause. Percentage of participants who died due to any cause were reported.</description>
          <population>Analysis was performed on full analysis set (FAS) that was defined as participants included in the safety analysis set who were randomised to the AdreView™ group or the SoC group.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="164"/>
                <count group_id="O2" value="157"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.0"/>
                    <measurement group_id="O2" value="3.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Analysis was performed using the Cox proportional hazards model stratified by country, with method of treatment guidance (SoC vs AdreView™ group) as the only covariate.</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority of AdreView™ group over SoC group was demonstrated if upper bound of the 95% confidence interval (CI) for the hazard ratio (HR) (AdreView™ group / SoC) was equal to 1.20.</non_inferiority_desc>
            <p_value>0.8459</p_value>
            <p_value_desc>Threshold for significance at 0.025 level.</p_value_desc>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.047</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.295</ci_lower_limit>
            <ci_upper_limit>3.719</ci_upper_limit>
            <estimate_desc>AdreView™ vs. Standard of Care</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Events of Complications of Device: H/M &gt;=1.6 in Full Analysis Set</title>
        <description>Composite of the percentage of participants with events of hospitalization or death related to major complications of device implantation (i.e., need for thoracotomy, pericardiocentesis, or vascular surgery), complications of long-term device therapy (i.e., infection not leading to hospitalization, lead and/or generator removal/replacement, inappropriate shocks, explanation), and combined as 'complications of device' for participants with H/M &gt;=1.6. Participants who were alive at time of database lock (DBL) were censored at the last known-alive date.</description>
        <time_frame>From randomization until the end of the follow-up period (median 304 days)</time_frame>
        <population>Analysis was performed on FAS population. Here, overall number of participants analyzed = participants with H/M &gt;=1.6.</population>
        <group_list>
          <group group_id="O1">
            <title>AdreView™</title>
            <description>Participants received 1 intravenous injection of 10 mCi (370 MBq) of AdreView™ (Iobenguane I-123 Injection). Participants with AdreView™ H/M ratio &lt;1.6 underwent ICD device implantation and H/M ratio &gt;= 1.6 continued to receive GDMT according to clinical standard practice.</description>
          </group>
          <group group_id="O2">
            <title>Standard of Care</title>
            <description>Participants received 1 intravenous injection of 10 mCi (370 MBq) of AdreView™ (Iobenguane I-123 Injection) and underwent ICD implantation and were followed up in accordance with internationally accepted HF guidelines.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Events of Complications of Device: H/M &gt;=1.6 in Full Analysis Set</title>
          <description>Composite of the percentage of participants with events of hospitalization or death related to major complications of device implantation (i.e., need for thoracotomy, pericardiocentesis, or vascular surgery), complications of long-term device therapy (i.e., infection not leading to hospitalization, lead and/or generator removal/replacement, inappropriate shocks, explanation), and combined as 'complications of device' for participants with H/M &gt;=1.6. Participants who were alive at time of database lock (DBL) were censored at the last known-alive date.</description>
          <population>Analysis was performed on FAS population. Here, overall number of participants analyzed = participants with H/M &gt;=1.6.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Hospitalization/death</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.8"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Complications of long-term device therapy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.8"/>
                    <measurement group_id="O2" value="15.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Complications of device</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.8"/>
                    <measurement group_id="O2" value="15.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Cardiac Death</title>
        <description>Cardiac death composed of sudden cardiac death, death due to cardiac arrhythmia, death due to heart failure, and death due to other cardiovascular causes.</description>
        <time_frame>From randomization until the end of the follow-up period (median 304 days)</time_frame>
        <population>Analysis was performed on FAS population.</population>
        <group_list>
          <group group_id="O1">
            <title>AdreView™</title>
            <description>Participants received 1 intravenous injection of 10 mCi (370 MBq) of AdreView™ (Iobenguane I-123 Injection). Participants with AdreView™ H/M ratio &lt;1.6 underwent ICD device implantation and H/M ratio &gt;= 1.6 continued to receive GDMT according to clinical standard practice.</description>
          </group>
          <group group_id="O2">
            <title>Standard of Care</title>
            <description>Participants received 1 intravenous injection of 10 mCi (370 MBq) of AdreView™ (Iobenguane I-123 Injection) and underwent ICD implantation and were followed up in accordance with internationally accepted HF guidelines.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Cardiac Death</title>
          <description>Cardiac death composed of sudden cardiac death, death due to cardiac arrhythmia, death due to heart failure, and death due to other cardiovascular causes.</description>
          <population>Analysis was performed on FAS population.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="164"/>
                <count group_id="O2" value="157"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.2"/>
                    <measurement group_id="O2" value="0.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Hospitalization for Cardiovascular Cause</title>
        <description>Percentage of participants who were hospitalized for cardiovascular cause were reported.</description>
        <time_frame>From randomization until the end of the follow-up period (median 304 days)</time_frame>
        <population>Analysis was performed on FAS population.</population>
        <group_list>
          <group group_id="O1">
            <title>AdreView™</title>
            <description>Participants received 1 intravenous injection of 10 mCi (370 MBq) of AdreView™ (Iobenguane I-123 Injection). Participants with AdreView™ H/M ratio &lt;1.6 underwent ICD device implantation and H/M ratio &gt;= 1.6 continued to receive GDMT according to clinical standard practice.</description>
          </group>
          <group group_id="O2">
            <title>Standard of Care</title>
            <description>Participants received 1 intravenous injection of 10 mCi (370 MBq) of AdreView™ (Iobenguane I-123 Injection) and underwent ICD implantation and were followed up in accordance with internationally accepted HF guidelines.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Hospitalization for Cardiovascular Cause</title>
          <description>Percentage of participants who were hospitalized for cardiovascular cause were reported.</description>
          <population>Analysis was performed on FAS population.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="164"/>
                <count group_id="O2" value="157"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.3"/>
                    <measurement group_id="O2" value="7.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With All-Cause Hospitalization</title>
        <description>Percentage of participants with all-cause hospitalization were reported.</description>
        <time_frame>From randomization until the end of the follow-up period (median 304 days)</time_frame>
        <population>Analysis was performed on FAS population.</population>
        <group_list>
          <group group_id="O1">
            <title>AdreView™</title>
            <description>Participants received 1 intravenous injection of 10 mCi (370 MBq) of AdreView™ (Iobenguane I-123 Injection). Participants with AdreView™ H/M ratio &lt;1.6 underwent ICD device implantation and H/M ratio &gt;= 1.6 continued to receive GDMT according to clinical standard practice.</description>
          </group>
          <group group_id="O2">
            <title>Standard of Care</title>
            <description>Participants received 1 intravenous injection of 10 mCi (370 MBq) of AdreView™ (Iobenguane I-123 Injection) and underwent ICD implantation and were followed up in accordance with internationally accepted HF guidelines.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With All-Cause Hospitalization</title>
          <description>Percentage of participants with all-cause hospitalization were reported.</description>
          <population>Analysis was performed on FAS population.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="164"/>
                <count group_id="O2" value="157"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.1"/>
                    <measurement group_id="O2" value="22.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Events (Composite of the Occurrence of Resuscitated Life-Threatening Ventricular Tachycardia, Unstable Ventricular Tachyarrhythmias, Sudden Cardiac Death [SCD] and Resuscitated Cardiac Arrest)</title>
        <description>Percentage of participants with composite events i.e occurrence of resuscitated life-threatening ventricular tachycardia, unstable ventricular tachy-arrhythmias, SCD and resuscitated cardiac arrest were reported. Participants who were alive at time of database lock (DBL) were censored at the last known-alive date.</description>
        <time_frame>From randomization until the end of the follow-up period (median 304 days)</time_frame>
        <population>Analysis was performed on FAS population.</population>
        <group_list>
          <group group_id="O1">
            <title>AdreView™</title>
            <description>Participants received 1 intravenous injection of 10 mCi (370 MBq) of AdreView™ (Iobenguane I-123 Injection). Participants with AdreView™ H/M ratio &lt;1.6 underwent ICD device implantation and H/M ratio &gt;= 1.6 continued to receive GDMT according to clinical standard practice.</description>
          </group>
          <group group_id="O2">
            <title>Standard of Care</title>
            <description>Participants received 1 intravenous injection of 10 mCi (370 MBq) of AdreView™ (Iobenguane I-123 Injection) and underwent ICD implantation and were followed up in accordance with internationally accepted HF guidelines.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Events (Composite of the Occurrence of Resuscitated Life-Threatening Ventricular Tachycardia, Unstable Ventricular Tachyarrhythmias, Sudden Cardiac Death [SCD] and Resuscitated Cardiac Arrest)</title>
          <description>Percentage of participants with composite events i.e occurrence of resuscitated life-threatening ventricular tachycardia, unstable ventricular tachy-arrhythmias, SCD and resuscitated cardiac arrest were reported. Participants who were alive at time of database lock (DBL) were censored at the last known-alive date.</description>
          <population>Analysis was performed on FAS population.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="164"/>
                <count group_id="O2" value="157"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.2"/>
                    <measurement group_id="O2" value="2.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Syncope</title>
        <description>Percentage of participants with Syncope were reported. Participants who were alive at time of DBL were censored at the last known-alive date by date of DBL.</description>
        <time_frame>From randomization until the end of the follow-up period (median 304 days)</time_frame>
        <population>Analysis was performed on FAS population.</population>
        <group_list>
          <group group_id="O1">
            <title>AdreView™</title>
            <description>Participants received 1 intravenous injection of 10 mCi (370 MBq) of AdreView™ (Iobenguane I-123 Injection). Participants with AdreView™ H/M ratio &lt;1.6 underwent ICD device implantation and H/M ratio &gt;= 1.6 continued to receive GDMT according to clinical standard practice.</description>
          </group>
          <group group_id="O2">
            <title>Standard of Care</title>
            <description>Participants received 1 intravenous injection of 10 mCi (370 MBq) of AdreView™ (Iobenguane I-123 Injection) and underwent ICD implantation and were followed up in accordance with internationally accepted HF guidelines.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Syncope</title>
          <description>Percentage of participants with Syncope were reported. Participants who were alive at time of DBL were censored at the last known-alive date by date of DBL.</description>
          <population>Analysis was performed on FAS population.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="164"/>
                <count group_id="O2" value="157"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.4"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Implantable Cardioverter Defibrillator (ICD) Implantation</title>
        <description>Percentage of participants with ICD implantation were reported.</description>
        <time_frame>From randomization until the end of the follow-up period (median 304 days)</time_frame>
        <population>Analysis was performed on FAS population.</population>
        <group_list>
          <group group_id="O1">
            <title>AdreView™</title>
            <description>Participants received 1 intravenous injection of 10 mCi (370 MBq) of AdreView™ (Iobenguane I-123 Injection). Participants with AdreView™ H/M ratio &lt;1.6 underwent ICD device implantation and H/M ratio &gt;= 1.6 continued to receive GDMT according to clinical standard practice.</description>
          </group>
          <group group_id="O2">
            <title>Standard of Care</title>
            <description>Participants received 1 intravenous injection of 10 mCi (370 MBq) of AdreView™ (Iobenguane I-123 Injection) and underwent ICD implantation and were followed up in accordance with internationally accepted HF guidelines.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Implantable Cardioverter Defibrillator (ICD) Implantation</title>
          <description>Percentage of participants with ICD implantation were reported.</description>
          <population>Analysis was performed on FAS population.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="164"/>
                <count group_id="O2" value="157"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73.2"/>
                    <measurement group_id="O2" value="81.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Events of Complications of Device</title>
        <description>Composite of the percentage of participants with events of hospitalization or death related to major complications of device implantation (i.e., need for thoracotomy, pericardiocentesis, or vascular surgery), complications of long-term device therapy (i.e., infection not leading to hospitalization, lead and/or generator removal/replacement, inappropriate shocks, explanation), and combined as 'complications of device'.</description>
        <time_frame>From randomization until the end of the follow-up period (median 304 days)</time_frame>
        <population>Analysis was performed on FAS population.</population>
        <group_list>
          <group group_id="O1">
            <title>AdreView™</title>
            <description>Participants received 1 intravenous injection of 10 mCi (370 MBq) of AdreView™ (Iobenguane I-123 Injection). Participants with AdreView™ H/M ratio &lt;1.6 underwent ICD device implantation and H/M ratio &gt;= 1.6 continued to receive GDMT according to clinical standard practice.</description>
          </group>
          <group group_id="O2">
            <title>Standard of Care</title>
            <description>Participants received 1 intravenous injection of 10 mCi (370 MBq) of AdreView™ (Iobenguane I-123 Injection) and underwent ICD implantation and were followed up in accordance with internationally accepted HF guidelines.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Events of Complications of Device</title>
          <description>Composite of the percentage of participants with events of hospitalization or death related to major complications of device implantation (i.e., need for thoracotomy, pericardiocentesis, or vascular surgery), complications of long-term device therapy (i.e., infection not leading to hospitalization, lead and/or generator removal/replacement, inappropriate shocks, explanation), and combined as 'complications of device'.</description>
          <population>Analysis was performed on FAS population.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="164"/>
                <count group_id="O2" value="157"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Hospitalization/death</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.9"/>
                    <measurement group_id="O2" value="3.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Complications of long-term device therapy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.3"/>
                    <measurement group_id="O2" value="6.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Complications of device</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.5"/>
                    <measurement group_id="O2" value="6.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>All Adverse Events (AEs) were collected from randomization until the end of the follow-up period (median 304 days) regardless of seriousness or relationship to investigational product.</time_frame>
      <desc>Reported AEs and deaths are study-emergent AEs that is AEs and deaths that developed/worsened during any time after randomization until end of the follow-up period (median 304 days). Analysis was performed on safety population which included all participants who signed the informed consent form and met all the inclusion criteria and none of the exclusion criteria.</desc>
      <group_list>
        <group group_id="E1">
          <title>AdreView™</title>
          <description>Participants received 1 intravenous injection of 10 mCi (370 MBq) of AdreView™ (Iobenguane I-123 Injection). Participants with AdreView™ H/M ratio &lt;1.6 underwent ICD device implantation and H/M ratio &gt;= 1.6 continued to receive GDMT according to clinical standard practice.</description>
        </group>
        <group group_id="E2">
          <title>Standard of Care</title>
          <description>Participants received 1 intravenous injection of 10 mCi (370 MBq) of AdreView™ (Iobenguane I-123 Injection) and underwent ICD implantation and were followed up in accordance with internationally accepted HF guidelines.</description>
        </group>
        <group group_id="E3">
          <title>Total Participants</title>
          <description>All participants who were randomized in AdreView™ and Standard of Care group in addition with non-randomized participants who signed informed consent form.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 19.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="157"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="343"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="65" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="62" subjects_at_risk="157"/>
                <counts group_id="E3" subjects_affected="127" subjects_at_risk="343"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Iron deficiency anaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="343"/>
              </event>
              <event>
                <sub_title>Leukocytosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="343"/>
              </event>
              <event>
                <sub_title>Normochromic normocytic anaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="343"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="157"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="343"/>
              </event>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="157"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="343"/>
              </event>
              <event>
                <sub_title>Angina unstable</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="157"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="343"/>
              </event>
              <event>
                <sub_title>Arrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="157"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="343"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="157"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="343"/>
              </event>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="157"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="343"/>
              </event>
              <event>
                <sub_title>Cardiac disorder</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="157"/>
                <counts group_id="E3" subjects_affected="48" subjects_at_risk="343"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="157"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="343"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="157"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="343"/>
              </event>
              <event>
                <sub_title>Cardiac perforation</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="343"/>
              </event>
              <event>
                <sub_title>Cardiac ventricular thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="343"/>
              </event>
              <event>
                <sub_title>Cardio-respiratory arrest</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="343"/>
              </event>
              <event>
                <sub_title>Supraventricular tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="157"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="343"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="157"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="343"/>
              </event>
              <event>
                <sub_title>Ventricular arrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="157"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="343"/>
              </event>
              <event>
                <sub_title>Ventricular extrasystoles</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="343"/>
              </event>
              <event>
                <sub_title>Ventricular tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="157"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="343"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="343"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperthyroidism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="157"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="343"/>
              </event>
              <event>
                <sub_title>Hypothyroidism</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="157"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="343"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="157"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="343"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="343"/>
              </event>
              <event>
                <sub_title>Chronic gastritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="343"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="157"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="343"/>
              </event>
              <event>
                <sub_title>Dental caries</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="343"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="343"/>
              </event>
              <event>
                <sub_title>Diverticulum</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="343"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="343"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="343"/>
              </event>
              <event>
                <sub_title>Enteritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="343"/>
              </event>
              <event>
                <sub_title>Gastroduodenal ulcer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="343"/>
              </event>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="343"/>
              </event>
              <event>
                <sub_title>Gastrointestinal ulcer haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="343"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="343"/>
              </event>
              <event>
                <sub_title>Haemorrhoids</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="157"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="343"/>
              </event>
              <event>
                <sub_title>Incarcerated inguinal hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="157"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="343"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="157"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="343"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="343"/>
              </event>
              <event>
                <sub_title>Rectal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="343"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="157"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="343"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest discomfort</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="157"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="343"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="343"/>
              </event>
              <event>
                <sub_title>Complication associated with device</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="157"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="343"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="343"/>
              </event>
              <event>
                <sub_title>Medical device site irritation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="157"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="343"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="343"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="157"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="343"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="343"/>
              </event>
              <event>
                <sub_title>Polyp</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="343"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="343"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="343"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="343"/>
              </event>
              <event>
                <sub_title>Device related infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="157"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="343"/>
              </event>
              <event>
                <sub_title>Endocarditis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="343"/>
              </event>
              <event>
                <sub_title>Gangrene</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="157"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="343"/>
              </event>
              <event>
                <sub_title>Helicobacter infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="157"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="343"/>
              </event>
              <event>
                <sub_title>Implant site infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="157"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="343"/>
              </event>
              <event>
                <sub_title>Incision site infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="343"/>
              </event>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="157"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="343"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="157"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="343"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="157"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="343"/>
              </event>
              <event>
                <sub_title>Otitis media</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="343"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="157"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="343"/>
              </event>
              <event>
                <sub_title>Post procedural cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="157"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="343"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="157"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="343"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="343"/>
              </event>
              <event>
                <sub_title>Septic shock</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="157"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="343"/>
              </event>
              <event>
                <sub_title>Streptococcal bacteraemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="157"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="343"/>
              </event>
              <event>
                <sub_title>Subcutaneous abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="343"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="157"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="343"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="343"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="343"/>
              </event>
              <event>
                <sub_title>Viral upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="343"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Humerus fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="157"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="343"/>
              </event>
              <event>
                <sub_title>Injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="343"/>
              </event>
              <event>
                <sub_title>Lower limb fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="343"/>
              </event>
              <event>
                <sub_title>Overdose</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="157"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="343"/>
              </event>
              <event>
                <sub_title>Sternal fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="343"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood cholesterol increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="343"/>
              </event>
              <event>
                <sub_title>Blood creatinine increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="343"/>
              </event>
              <event>
                <sub_title>Blood uric acid increased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="343"/>
              </event>
              <event>
                <sub_title>C-reactive protein increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="343"/>
              </event>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="157"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="343"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Cachexia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="157"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="343"/>
              </event>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="343"/>
              </event>
              <event>
                <sub_title>Diabetes mellitus</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="343"/>
              </event>
              <event>
                <sub_title>Diabetes mellitus inadequate control</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="157"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="343"/>
              </event>
              <event>
                <sub_title>Dyslipidaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="157"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="343"/>
              </event>
              <event>
                <sub_title>Gout</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="157"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="343"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="157"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="343"/>
              </event>
              <event>
                <sub_title>Hyperkalaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="157"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="343"/>
              </event>
              <event>
                <sub_title>Hyperuricaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="157"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="343"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="157"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="343"/>
              </event>
              <event>
                <sub_title>Lactic acidosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="343"/>
              </event>
              <event>
                <sub_title>Type 2 diabetes mellitus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="157"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="343"/>
              </event>
              <event>
                <sub_title>Vitamin D deficiency</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="157"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="343"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="343"/>
              </event>
              <event>
                <sub_title>Dupuytren's contracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="343"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="157"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="343"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="343"/>
              </event>
              <event>
                <sub_title>Rhabdomyolysis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="343"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Colon cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="157"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="343"/>
              </event>
              <event>
                <sub_title>Gastrointestinal stro</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="157"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="343"/>
              </event>
              <event>
                <sub_title>Lung neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="343"/>
              </event>
              <event>
                <sub_title>Neoplasm prostate</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="157"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="343"/>
              </event>
              <event>
                <sub_title>Prostate cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="157"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="343"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="157"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="343"/>
              </event>
              <event>
                <sub_title>Dementia Alzheimer's type</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="343"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="343"/>
              </event>
              <event>
                <sub_title>Epilepsy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="343"/>
              </event>
              <event>
                <sub_title>Hemiplegia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="343"/>
              </event>
              <event>
                <sub_title>Presyncope</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="343"/>
              </event>
              <event>
                <sub_title>Seizure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="157"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="343"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="157"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="343"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="157"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="343"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Product Issues</title>
            <event_list>
              <event>
                <sub_title>Device inappropriate shock delivery</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="157"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="343"/>
              </event>
              <event>
                <sub_title>Device use issue</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="157"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="343"/>
              </event>
              <event>
                <sub_title>Lead dislodgement</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="157"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="343"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="343"/>
              </event>
              <event>
                <sub_title>Confusional state</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="343"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="157"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="343"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute kidney injury</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="157"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="343"/>
              </event>
              <event>
                <sub_title>Renal impairment</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="343"/>
              </event>
              <event>
                <sub_title>Urinary bladder haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="157"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="343"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Benign prostatic hyperplasia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="157"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="343"/>
              </event>
              <event>
                <sub_title>Prostatitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="343"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute pulmonary oedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="157"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="343"/>
              </event>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="157"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="343"/>
              </event>
              <event>
                <sub_title>Bronchospasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="157"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="343"/>
              </event>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="157"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="343"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="343"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="343"/>
              </event>
              <event>
                <sub_title>Dyspnoea paroxysmal nocturnal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="157"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="343"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="157"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="343"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="343"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="343"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="157"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="343"/>
              </event>
              <event>
                <sub_title>Pulmonary mass</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="343"/>
              </event>
              <event>
                <sub_title>Pulmonary oedema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="343"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="157"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="343"/>
              </event>
              <event>
                <sub_title>Sinus congestion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="157"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="343"/>
              </event>
              <event>
                <sub_title>Sleep apnoea syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="343"/>
              </event>
              <event>
                <sub_title>Tachypnoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="343"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="157"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="343"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Implantable defibrillator insertion</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="157"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="343"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Aortic aneurysm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="343"/>
              </event>
              <event>
                <sub_title>Aortic dissection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="157"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="343"/>
              </event>
              <event>
                <sub_title>Circulatory collapse</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="343"/>
              </event>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="343"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="157"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="343"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="157"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="343"/>
              </event>
              <event>
                <sub_title>Intermittent claudication</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="157"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="343"/>
              </event>
              <event>
                <sub_title>Lymphoedema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="343"/>
              </event>
              <event>
                <sub_title>Orthostatic hypotension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="157"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="343"/>
              </event>
              <event>
                <sub_title>Peripheral artery stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="157"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="343"/>
              </event>
              <event>
                <sub_title>Peripheral ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="343"/>
              </event>
              <event>
                <sub_title>Phlebitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="343"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="343"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI and/or institution is that the Sponsor can review results communications prior to public release and can restrict communications regarding trial results for a period that is more than 30 days (publications/abstracts) but not to exceed 90 days (patent related issues) from the time submitted to the Sponsor to review. The PI may be asked to remove any Sponsor confidential information and/or delay publication to protect any proprietary information.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The study was early terminated by sponsor after enrollment of 395 participants due to very slow recruitment rates. Sample size was 395 participants instead of planned 2354 participants.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Francois Tranquart, M.D., Ph.D.</name_or_title>
      <organization>GE Healthcare</organization>
      <phone>0-44-1494-543037</phone>
      <email>francois.tranquart@ge.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

